NCT01030718View on ClinicalTrials.gov

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Chronic Myelogenous LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
Interventions
DRUG

dasatinib

Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY